

Vaccine nationalism and the dynamics and control of SARS-CoV-2

Caroline E. Wagner,^{1,*†} Chadi M. Saad-Roy,^{2,*†} Sinead E. Morris,³
Rachel E. Baker,^{4,5} Michael J. Mina,⁶ Jeremy Farrar,⁷ Edward C. Holmes,⁸
Oliver G. Pybus,⁹ Andrea L. Graham,⁴ Ezekiel J. Emanuel,¹⁰ Simon A. Levin,⁴
C. Jessica E. Metcalf,^{4,11} Bryan T. Grenfell^{4,11,†}

¹ Department of Bioengineering, McGill University, Montreal QC H3A 0C3, Canada

² Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton NJ 08540, USA

³ Department of Pathology and Cell Biology,

Columbia University Medical Center, New York NY 10032, USA

⁴ Department of Ecology and Evolutionary Biology, Princeton University, Princeton NJ 08540, USA

⁵ Princeton High Meadows Environmental Institute, Princeton University, Princeton NJ 08540, USA

⁶ Departments of Epidemiology and Immunology and Infectious Diseases,
Harvard T. H. Chan School of Public Health, Boston MA 02115, USA

⁷ The Wellcome Trust, London, UK

⁸ Marie Bashir Institute for Infectious Diseases and Biosecurity,
School of Life and Environmental Sciences and School of Medical Sciences,
The University of Sydney, Sydney, NSW, Australia

⁹ Department of Zoology, University of Oxford, Oxford, UK

¹⁰ Department of Medical Ethics and Health Policy,
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

¹¹ Princeton School of Public and International Affairs,
Princeton University, Princeton NJ 08540, USA

*These authors contributed equally to this work;

†To whom correspondence should be addressed:

caroline.wagner@mcgill.ca (CEW); csaadroy@princeton.edu (CMSR);

grenfell@princeton.edu (BTG)

1 **Vaccines provide powerful tools to mitigate the enormous public health and**
2 **economic costs that the ongoing SARS-CoV-2 pandemic continues to exert**
3 **globally, yet vaccine distribution remains unequal between countries. To ex-**
4 **amine the potential epidemiological and evolutionary impacts of ‘vaccine na-**
5 **tionalism’, we extend previous models to include simple scenarios of stock-**
6 **piling. In general, we find that stockpiling vaccines by countries with high**
7 **availability leads to large increases in infections in countries with low vac-**
8 **cine availability, the magnitude of which depends on the strength and duration**
9 **of natural and vaccinal immunity. Additionally, a number of subtleties arise**
10 **when the populations and transmission rates in each country differ depending**
11 **on evolutionary assumptions and vaccine availability. Furthermore, the move-**
12 **ment of infected individuals between countries combined with the possibility of**
13 **increases in viral transmissibility may greatly magnify local and combined in-**
14 **fection numbers, suggesting that countries with high vaccine availability must**
15 **invest in surveillance strategies to prevent case importation. Dose-sharing is**
16 **likely a high-return strategy because equitable allocation brings non-linear**
17 **benefits and also alleviates costs of surveillance (e.g. border testing, genomic**
18 **surveillance) in settings where doses are sufficient to maintain cases at low**
19 **numbers. Across a range of immunological scenarios, we find that vaccine**
20 **sharing is also a powerful tool to decrease the potential for antigenic evolution,**
21 **especially if infections after the waning of natural immunity contribute most to**
22 **evolutionary potential. Overall, our results stress the importance of equitable**
23 **global vaccine distribution.**

24 The SARS-CoV-2 pandemic has led to more than 100 million infections and nearly 3 million
25 fatalities to date (1). Effective vaccines (e.g. (2–4)) have now been approved and are actively
26 being deployed, but numerous important questions remain. Eventually, community immunity

27 may be attained through the deployment of vaccines; however if and when this occurs will be
28 contingent on the characteristics of natural and vaccinal immunity (5–7) in conjunction with
29 SARS-CoV-2 evolutionary potential.

30

31 Due to strong public and political pressures and fear of waning immunity, some countries
32 with high vaccine availability are currently resorting to ‘vaccine nationalism’: stockpiling vac-
33 cines to prioritize rapid access to their citizenry (8). Recently, the World Health Organization
34 recognized that delayed access to vaccines in countries with low vaccine availability may lead
35 to more evolutionary potential for immune escape (9). Indeed, at the time of writing, 86 and
36 91 doses per 100 individuals have been administered in the United States and United Kingdom,
37 respectively, while an average of 14 and 2.1 doses per 100 individuals have been administered
38 in India and across Africa, respectively (10). The emergence of future variants capable of evad-
39 ing natural or vaccinal immune responses could threaten containment efforts globally. These
40 concepts underlie the development of a number of policy tools, including the existing COVAX
41 initiative. Furthermore, to ensure that vaccine distribution is ethically-sound and equitable, the
42 “Fair Priority Model” has been proposed (11–13) as a potential replacement to the currently
43 planned proportional allocation (by population size) from COVAX.

44

45 Prior work exploring optimal prophylactic vaccine allocation for minimizing the final epi-
46 demic size of a fully immunizing infection (i.e. one that can be modeled using a susceptible-
47 infected-recovered (SIR) framework) found that when interaction between communities (or
48 countries) is considered, equal vaccine distribution is increasingly advantageous in terms of
49 minimizing case numbers (14). Modeling studies have also shown that coordinated influenza
50 vaccine sharing would reduce the financial and infection burden of influenza outbreaks glob-
51 ally (15). Similar problems related to optimizing vaccine allocation have also been explored in
52 networks with community structure (16) as well as in the face of economic constraints (17) and

53 coalition formation (18), and for SARS-CoV-2 with age- (and contact-) structure (19, 20). We
54 have recently shown that the strength and duration of immunity elicited following infection or
55 one or two doses of a vaccine will have a crucial impact on the medium-term epidemiological
56 and potential evolutionary outcomes (5, 6). Here we extend these analyses to address potential
57 epidemiological and evolutionary consequences of policies of vaccine nationalism or equitable
58 access for a range of assumptions regarding the robustness of host immune responses. In real-
59 ity, vaccine distribution is a public goods problem, and the optimal “global” allocation projected
60 based on evolutionary and immunological uncertainties may differ from national optima due to
61 the actual economic landscape of each country. In all cases, however, the reduction in the po-
62 tential for novel strains to arise associated with minimizing the global infection burden is likely
63 critical.

64




Figure 1: Schematic depicting the two-country model. The underlying immuno-epidemiological models for each country are based on (5, 6). Vaccines are allocated by the high access region (HAR) to the low access region (LAR). In the coupled framework, immigration of infected individuals between the countries is considered, and the national transmission rate depends on potential transmission increases (PTIs) in both countries, shown schematically as solid and striped virus particles in the HAR and LAR, respectively. In the decoupled framework, no immigration occurs, and the transmission rate is not influenced by PTIs. Full model details are provided in the Supplementary Materials.

65 We consider a trans-national extension of our model comprised of two countries with possi-
 66 bly different population sizes and seasonal transmission patterns. One country, the high access
 67 region (HAR), chooses to allocate a fraction f of the total vaccine supply to the low access
 68 region (LAR). The underlying immuno-epidemiological models for both countries account for
 69 both the duration of natural and vaccinal immunity and the residual decrease in host suscepti-
 70 bility to infection (relative to immunologically naive individuals) after full natural or vaccinal
 71 immunity has waned; these models are described in detail in (5, 6), where the more detailed
 72 structure (6) accounts for immunity after one or two vaccine doses. In the first “decoupled”
 73 framework (top panel of Figure 1), we assume that the epidemiological dynamics of both coun-

74 tries are entirely independent with the exception of their respective vaccination rates, and we
75 also compute a measure for the global potential for viral evolution of immune escape (6). In the
76 second “coupled” framework (bottom panel of Figure 1), we allow for immigration of infected
77 individuals between the countries at rate η (17). Additionally, we approximate the stochastic
78 occurrence of potential transmission increases (PTIs) in each country: briefly, if the ‘potential
79 net viral adaptation rate’ (see Supplementary Materials, Figure 5, and (6)) exceeds a thresh-
80 old, then there is a non-zero probability that the transmission rate in both countries increases.
81 This follows evidence of enhanced binding of the SARS-CoV-2 spike protein receptor binding
82 domain (RBD) with the ACE2 receptor in more contagious SARS-CoV-2 variants, as well as
83 potentially higher viral loads (21). Structural changes to the spike protein furin cleavage site
84 (e.g. at site 681) may also contribute to increased viral transmissibility (22). In this way, this
85 assumption represents a pessimistic scenario where the evolution of pathogen immune escape
86 is inevitably accompanied by increases in transmission, although we also compare our results
87 with the more optimistic scenario where transmission increases do not occur (note that we are
88 not modeling the complexities of variant dynamics and evolution explicitly). In reality, trans-
89 mission increases may plateau, and viral evolution may have more subtle effects on disease
90 transmission including modulating the susceptibility of partially immune hosts. The full math-
91 ematical details for both frameworks are described in the Supplementary Materials.

92

93 We begin with the decoupled framework and the simpler underlying ‘one-dose’ vaccination
94 model from (5) to compute the long-term equilibrium fraction of infections in both countries
95 under a range of epidemiological and immunological scenarios. Then, with specific dosing
96 regimes (6), we examine the short- and medium-term epidemiological dynamics and the global
97 potential for evolution with the sharing of vaccines. Next, using the coupled framework, we
98 compute national and combined case numbers in the medium term given different degrees of
99 vaccine allocation from the HAR to the LAR for different immigration rates and average relative

100 reproduction numbers. We do so for total as well as severe cases, with the expectation that the
101 number of severe cases may be indicative of infections requiring hospitalization or the clinical
102 burden of Covid-19, while the number of total cases reflects all infections regardless of severity.
103 Finally, we compare the results of the coupled and decoupled frameworks for specific scenarios.

104 **Results and Discussion**

105 **Decoupled Framework**

106 The dynamics of prophylactic vaccine distribution strategies are well understood when infec-
107 tions lead to recovery and lifelong immune protection (SIR) (14). However, natural and vaccinal
108 immunity to SARS-CoV-2 is likely not lifelong, yet complete re-susceptibility after the waning
109 of immunity, as is assumed in susceptible-infected-recovered-susceptible (SIRS) frameworks,
110 is also unlikely. Thus, we generalize across the strength and duration of immune responses with
111 appropriate mathematical models (5, 6). We first ignore the complexities of dosing regimes and
112 extend the model in (5) to consider vaccine sharing in the decoupled framework (top panel of
113 Figure 1) under the assumption that a single immune category exists for vaccinated individu-
114 als, and that vaccinal immunity may wane at a rate distinct from natural immunity. Since we
115 assume that the infection dynamics in both countries are only coupled through their respective
116 vaccination rates, a unique equilibrium of total infections exists (either disease-free or endemic;
117 see supplement and (5) for details). To examine the long-term epidemiological effects of vac-
118 cine nationalism, we compute the total fraction of infections at equilibrium as the proportion of
119 vaccines shared between countries is varied. In other words, for a fixed global vaccination rate
120 ν_{tot} (determined by the maximal rate of administration of the first dose $\nu_{0,\text{tot}}$ and the inter-dose
121 period, see Methods) and for a fraction f of vaccines allocated from the HAR to the LAR, the
122 vaccination rates in the HAR and LAR are $(1 - f)\nu_{\text{tot}}$ and $f\nu_{\text{tot}}$, respectively. We examine four
123 immunity scenarios that range from very poor to robust natural and vaccinal immune responses
124 (Figure 2).

125

126 When the characteristics of both countries are the same, sharing vaccines always decreases
127 or maintains the total fraction of infections at the long-term equilibrium (see Keeling (14) for
128 the SIR extreme with a focus on two differently-sized populations). The intuition for this result
129 is apparent from examining the underlying values for each country (Figure 2C). The total frac-
130 tion of infections are minimized whenever one of the countries does not vaccinate beyond the
131 rate needed for herd immunity. Additionally, sharing does not have an appreciable impact on
132 the total fraction of infections at equilibrium when vaccination rates are too low (Figure 2A, top
133 panel), or overall transmission rates are more elevated and host immune responses are poorer
134 (Figure 2B, top panel). Because of nonpharmaceutical interventions (NPIs) or intrinsic factors
135 (e.g. population density (23) or vulnerabilities (24)), transmission rates in the two countries may
136 be asymmetric. If there is less disease transmission in the HAR (modelled as a reduction in the
137 transmission rate), then the ‘optimal’ fraction of vaccines shared to minimize the combined
138 equilibrium fraction of infections crucially depends on the magnitude of the vaccination rate.
139 If vaccine supplies are low and immune responses very poor, then sharing only a very small
140 fraction of the vaccine supply is epidemiologically beneficial in terms of decreasing the overall
141 burden. For stronger immune responses, augmenting vaccine sharing rates becomes increas-
142 ingly beneficial from an epidemiological perspective, as the protective effects of the vaccine are
143 maintained for longer within the population (compare the columns of the middle row of Figure
144 2A). Similarly, as vaccine supplies increase (compare the coloured curves in the middle row of
145 Figure 2A), the minimum value of infections occurs for increasingly large values of f , or frac-
146 tions of vaccines shared. Eventually, when global vaccination rates are high, even for very poor
147 host immune responses, this minimum is attained when more than half of the vaccine supply is
148 allocated to the LAR (leftmost panel of middle row of Figure 2A). By symmetry, the opposite
149 occurs if there is less transmission in the LAR. These trends are further magnified if overall
150 transmission rates are increased (Figure 2B). To further emphasize these effects, we present




Figure 2: Long-term equilibrium of the average fraction of infections. In all panels, immunity scenarios are as follows: *very poor immunity*, $\frac{1}{\delta} = \frac{1}{\delta_{\text{vax}}} = 0.8$ years, $\epsilon = 0.8$; *poor immunity*, $\frac{1}{\delta} = \frac{1}{\delta_{\text{vax}}} = 1$ year, $\epsilon = 0.7$; *intermediate immunity*, $\frac{1}{\delta} = \frac{1}{\delta_{\text{vax}}} = 1.5$ years, $\epsilon = 0.6$; *robust immunity*, $\frac{1}{\delta} = \frac{1}{\delta_{\text{vax}}} = 2$ years, $\epsilon = 0.5$. In the scenario with asymmetrical transmission rates between the two countries, the transmission rate in the country with lower transmission is taken to be 80% of the value in the symmetric case. In the scenarios with overall higher transmission rates (panel B), this same asymmetric assumption is made in addition to the baseline symmetric transmission rate being elevated by 30% relative to the value in panels (A). (C)–(E) Illustrations of the equilibrium fraction of infections in each country with the very poor immunity scenario, for: (C) symmetric transmission with $\nu_{\text{tot}} = 0.004$; (D) asymmetric transmission (lower in HAR) with $\nu_{\text{tot}} = 0.004$; (E) asymmetric transmission (lower in HAR) with $\nu_{\text{tot}} = 0.001$; with all other parameters as in panel A. In all panels, the baseline transmission rate is $\beta = \frac{2.3}{5}$.

151 the long-term equilibrium of each country under representative scenarios in Figures 2C–2E. In
152 particular, the comparison between Figures 2D and 2E illustrates the importance, and indirect
153 benefit, of increasing vaccine supply. The relative sizes of the HAR and LAR populations can
154 have important consequences for the fraction of vaccine allocation that minimizes the weighted
155 fraction of infections (Fig. S1, S2). Overall, these results highlight the importance of continued
156 NPIs that decrease transmission, such as rapid-testing and physical distancing, in conjunction
157 with ramping up vaccination and sharing vaccine supplies equitably to decrease overall burden.

158

159 To consider the near- and medium-term dynamic epidemiological effects of vaccine shar-
160 ing, in Figure 3 we explore the landscapes of immunity and infections across multiple scenarios
161 for otherwise-symmetric countries (i.e. population size and seasonal transmission rates). In all
162 scenarios, vaccine supply is assumed to be limited initially in the HAR (modeled as a one dose
163 policy, a lower maximal rate of administration of the first dose $\nu_{0,\text{tot}}$, and no sharing ($f = 0$))
164 and then is assumed to increase. In conjunction with an increase in $\nu_{0,\text{tot}}$, we allow for a tran-
165 sition to the recommended two-dose strategy ($\frac{1}{\omega} = 4$ weeks, right two columns of Figure 3),
166 and/or the initiation of equal sharing ($f = 0.5$) with the LAR (which is assumed to distribute
167 vaccines using the same strategy as the HAR) may be initiated (second and fourth columns of
168 Figure 3).


169

170 Intuitively, if one-dose immunity is robust (bottom panel of Figure 3), then transitioning
171 to a two-dose strategy leads to fewer individuals with robust vaccinal immunity, in turn giving
172 rise to substantial increases in infections in both in the short- and medium-term (compare the
173 corresponding scenarios of the bottom panel of Figure 3 and see also (6)). In such a situation,
174 ‘one-dose’ strategies (i.e. either the first dose of a 2-dose vaccine or the unique dose of a 1-dose
175 vaccine) with equal sharing between countries suppress overall burden. On the other hand, if
176 one-dose immunity is poor, switching to the recommended two-dose regimen prevents the ac-

Poor vaccinal immunity after one dose

One-dose policy

Switch to two-dose strategy



Robust vaccinal immunity after one dose

One-dose policy

Switch to two-dose strategy




Figure 3: Immune landscapes and infections in both countries under a range of vaccination strategies and assumptions related to robustness of immune responses. Note that the color scheme is as in Figure 1. In all panels, vaccination begins after week 48. *Poor vaccinal immunity after one dose* is represented by $\frac{1}{\delta_1} = 0.25$ year and $\epsilon_1 = 0.9$, whereas *robust vaccinal immunity after one dose* means $\frac{1}{\delta_1} = 1$ year and $\epsilon_1 = 0.7$. All other parameters values including the procedure for the calculation of severe cases are described in Supplementary Materials. In both the top and bottom panels: the top row depicts a switch from a maximum first-dose administration rate of 1% to 3% after week 60, whereas it is 1% to 5% for the bottom row (and concurrent with sharing, if it occurs).

177 cumulation of individuals with waned one-dose immunity and thus potentially larger infections
178 peaks in the longer term (top panel, Figure 3). If poor one-dose immunity nevertheless reduces
179 severity of infection after waning (unlike our pessimistic assumption), then the predicted clin-
180 ical burden of severe cases would likely be lower. Finally, if one-dose immunity is poor and
181 a one-dose policy is pursued, the first infection peak after ramping up vaccination in the HAR
182 may be higher without sharing (top left panel of Figure 3). This counter-intuitive finding arises
183 due to the large accumulation of individuals with waned one-dose immunity who experience
184 infection. This highlights the important role for population-level susceptibility (modulated by
185 natural and vaccinal immune responses) and its dynamical interplay with transmission in deter-
186 mining the timing and burden of infections. The effects of different NPI scenarios, transmission
187 patterns, and vaccination rates in either the HAR or LAR can be further explored with the online
188 application (<https://grenfelllab.shinyapps.io/vaccine-nationalism/>).

189

190 The accumulation of individuals with various immunity phenotypes (i.e. waned one-dose
191 immunity or immunity following natural infection) may also lead to different evolutionary
192 outcomes depending on the vaccine sharing scheme pursued. Current evidence suggests that
193 adaptive immune responses following natural infection with SARS-CoV-2 are fairly robust and
194 long-lasting (25, 26), although this may be less certain in the context of subsequent infection
195 with variant strains (27, 28). Encouragingly, studies indicate that previously-infected hosts are
196 largely protected (clinically and against breakthrough infections) against emerging variants af-
197 ter a single vaccine dose (29). Thus far, the duration and strength of this protection towards
198 existing strains and potential emerging variants remain unknown. In Figure S3, we use the evo-
199 lutionary framework from (6) to project the potential net viral adaptation rate (see Methods and
200 online application for additional scenarios). Overall, we find that uncertainties in evolutionary
201 outcomes dominate our projections, echoing previous findings (6) (Figure S3, and online appli-
202 cation). However, if the evolutionary potential for immune escape is highest among infections

203 in hosts with natural immunity, then sharing vaccines always decreases global evolutionary po-
204 tential (Figure S3) in the decoupled framework. Overall, when immunity after a single vaccine
205 dose is robust, natural and vaccine-derived immunity will limit evolutionary advances relative
206 to the scenario with poor single dose immunity (compare the top and bottom panels of Figure
207 S3). However, if immunity is partial or waning, ongoing transmission might accelerate adap-
208 tion, supporting the need for continued monitoring of variants and their interaction with natural
209 and vaccine-derived immunity.

210

211 Another intuitive result is that, in the LAR, sharing vaccines leads to increases in population
212 immunity (for any dosing regime) and thus a decrease in infections and burden in the short
213 term, even with poor one-dose immunity. In general, in the HAR, sharing decreases population
214 immunity and increases infections in the short term. However, these changes are minimal and
215 likely acceptable given the combined decrease in infections, illustrating the long term benefits
216 of vaccine sharing.

217 **Coupled Framework**

218 So far, we have assumed that the countries have decoupled disease dynamics. This simplifica-
219 tion for tractability ignores infection importation as well as the possible emergence of variants
220 from regions with more persistent infections. The issues that arise from the global circulation
221 of SARS-CoV-2, particularly the variants of concern, are of considerable public health impor-
222 tance. Thus, we next explore these effects using the coupled framework presented in the bottom
223 panel of Figure 1.

224

225 In Figure 4, we plot the cumulative number of total and severe cases (see Supplementary
226 Materials for details) assuming equal population sizes in both countries from the time of vaccine
227 introduction until 5 years after the pandemic onset in the HAR, LAR, and combined, as well

228 as the projected number of PTIs to have occurred in both regions by the end of the 5 year
229 period. We do so for various vaccine allocation fractions between the HAR and LAR, as well
230 as a range of immigration rates assuming symmetric transmission rates (Figures 4A and 4C)
231 and relative mean reproduction numbers assuming constant immigration rates (Figures 4B and
232 4D, see Methods). In Figures 4A and 4B we assume that infection following waned natural
233 immunity contributes the most to viral adaptation, while in Figures 4C and 4D we assume that
234 infection following waned vaccinal immunity, and one-dose immunity in particular, contributes
235 the most.




Figure 4: Heat maps depicting total and severe cases from the time of vaccine onset ($t_{\text{vax}} = 48$ weeks) through the end of the 5 year period for both countries (leftmost two columns), the HAR (third and fourth columns from the left), the LAR (fifth and sixth columns from the left), as well as the combined number of PTIs to have occurred in both countries at the end of 5 years (rightmost column). Each grid-point denotes the mean value of 100 simulations. The population of both countries is taken to be the same. Each area plot is internally normalized, such that the largest value in each plot is 1. The x -axis indicates the fraction of vaccines retained by the HAR (i.e. $1 - f$); thus the far right of a plot is the scenario where the HAR retains all vaccines ($f = 0$). In A and C, both countries have the same average transmission rate (\bar{R}_0 , see Methods), and the immigration rate η is varied. In B and D, the immigration rate is fixed at $\eta = 0.01$, and the relative mean transmission rate in the LAR, i.e. $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$, is varied between 0.5 and 2. The seasonality of the transmission rates in both countries and periods of NPI adoption are identical and as described in the Methods. In all simulations, we assume a two-dose strategy throughout, i.e. $\frac{1}{\omega} = 4$ weeks, and take the maximal rate of administration of the first dose to be $\nu_{0,\text{tot}} = 2\%$. Assumed immunological parameters are $\frac{1}{\delta_1} = 1$ year, $\epsilon = 0.7$, $\epsilon_{V_1} = 0.1$, $\epsilon_{V_2} = 0.05$, $\epsilon_2 = 0.7$, $\frac{1}{p_2} = 1$ year, and the one- to two-dose immune response ratio is $x_e = 0.8$ (see Methods). In the top panel (A and B), we assume that infection after waned natural immunity contributes more to potential viral adaptation, and take $w_{IS} = 0.8$, $w_{IS1} = 0.2/x_e$, and $w_{IS2} = 0.2$ (see Methods). In the bottom panel (C and D), we assume that infection after waned vaccinal immunity contributes more to potential viral adaptation, and take $w_{IS} = 0.4$, $w_{IS1} = 0.8$, and $w_{IS2} = 0.8 \times x_e$ (see Methods). Additional details related to the determination of severe cases are also provided in Supplementary Materials.

236 For equal population sizes and symmetric transmission rates, a weak dependence of total
237 and severe cases as well as PTIs on the immigration rate η is observed, regardless of whether
238 infection after waned natural or vaccinal immunity is assumed to contribute more to viral evo-
239 lution (Figures 4A and 4C). Additionally, equal vaccine sharing (i.e. $f = 0.5$) minimizes total
240 PTIs and combined total cases in both scenarios. When natural infections contribute more to
241 evolution (Figure 4A) and η is low, the HAR must retain an increasing share of the vaccines to
242 minimize local total cases as the immigration rate increases, but this is done at the expense of
243 more cases in the LAR and PTIs. Notably, for $f \approx 0$, severe cases are minimized regardless
244 of the immigration rate in the HAR and maximized in the LAR, which may have important
245 clinical consequences. When infection following waned vaccinal immunity contributes more to
246 viral evolution, this approach is no longer advantageous for the HAR, and the retained vaccine
247 fraction sets the observed case numbers nearly independently of the assumed immigration rate.
248 Further, large asymmetries in vaccine sharing (i.e. $f = 0$ or $f = 1$) result in much more marked
249 relative numbers of PTIs in this scenario.

250

251 For the same total vaccine availability, the most realistic population asymmetry is that the
252 LAR has a larger population; this corresponds to low and middle income countries with more
253 fragile healthcare systems. Under this condition (Figure S4) and when infection after waned
254 natural immunity contributes more to evolution, total cases in the LAR are relatively insen-
255 sitive to the amount of vaccine allocated, except for very large f ; however severe cases can
256 be substantially reduced with vaccine sharing. Here, combined total cases and PTIs are mini-
257 mized by minimizing cases in the HAR. When a greater number of total vaccines are available
258 (i.e. a larger $\nu_{0,\text{tot}}$, Figure S5), total and severe cases in the more populous LAR decrease
259 approximately monotonically with increasing vaccine allocation f and more equitable vaccine
260 allocation once again minimizes combined total and severe cases. When infection after waned
261 vaccinal immunity contributes more to evolution, the trends are more similar to those for sym-

262 metric population sizes, and more equitable vaccine sharing is favoured for both vaccination
263 rates $\nu_{0,\text{tot}}$ given a larger population in the LAR (Figures S4 and S5).

264

265 When the LAR has a smaller population (Figure S6), a relatively weak dependence of total
266 and severe case numbers and PTIs on η is still observed for both evolutionary scenarios, par-
267 ticularly for higher immigration rates. However, and particularly when infection after waned
268 natural immunity contributes more to evolution, the minima in combined cases and PTIs are
269 now observed for $f < 0.5$, i.e. when the HAR retains more than half of the available vaccines.
270 Importantly, we note that additional booster doses may further change these landscapes of im-
271 munity, and consequently the projected burdens of total and severe cases.

272

273 The number of total and severe cases and PTIs show a greater sensitivity to the average
274 reproduction number ratio $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$ between the two countries for a fixed immigration
275 rate. Intuitively, for equal population sizes (Figure 4) and when \bar{R}_0 in the LAR country is lower,
276 having the HAR retain more than half of the vaccines ($f < 0.5$) is a good strategy for minimiz-
277 ing total PTIs and cases, regardless of the evolutionary scenario. Indeed, the optimal vaccine
278 allocation shifts closer and closer to equal sharing as the \bar{R}_0 values of both countries approach
279 each other, along with an increase in cases. These trends are similar when the LAR has a larger
280 or smaller population than the HAR (Figures S4 and S6, respectively).

281

282 When \bar{R}_0 in the LAR is higher, trends are more complex. In general, regardless of the rel-
283 ative population size or evolutionary scenario, for a given $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$, cases in the HAR
284 decrease with increasing vaccine retention (smaller f), while cases in the LAR increase (Fig-
285 ures 4, S4, S5, and S6). Severe cases in each region in particular are strongly reduced by
286 increased vaccine availability. The increase in cases in the LAR is increasingly large at higher
287 $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}}$. When infection after waned natural immunity contributes more to evolution

288 and vaccine supply is sufficiently high to reduce case numbers in the LAR, PTIs are numerous
289 when the HAR retains a large fraction of the vaccines (Figures 4B, S5B, and S6B). This is due
290 to sustained elevated case numbers in unvaccinated individuals in the LAR. On the other hand,
291 when infection following waned vaccinal immunity contributes more to evolution, then hav-
292 ing the HAR (with lower transmission rates) retain a larger fraction of the vaccines minimizes
293 PTIs for any relative population size, since the high \bar{R}_0 in the LAR would result in large subse-
294 quent peaks containing individuals whose vaccinal immunity has waned with sharing (Figures
295 4D, S4D, S5D, and S6D). However, this strategy also leads to highly elevated case numbers,
296 including severe cases, in the LAR.




Figure 5: Time series of cases and potential net viral adaptation rates. Top row: Infections in the HAR (blue) and LAR (red) for the first 5 years after pandemic onset for the coupled (left) and decoupled (middle) frameworks. Each simulation is run 100 times, with the average indicated by the solid line and the standard deviation shown with the corresponding ribbon. The average number of cumulative cases over all simulations from the time of vaccine onset $t_{\text{vax}} = 48$ weeks through the end of the 5 year period are shown in the rightmost figure for the HAR, LAR, and both countries combined for the coupled (solid) and decoupled (dashed) frameworks. Bottom row: Time series of the potential viral adaptation rate in both regions for the coupled (left) and decoupled (right) frameworks. The colors, averages and standard deviations are as described above. The dashed horizontal line denotes $e_{\text{cutoff}} = 0.01$, the assumed threshold for the occurrence of a PTI (see Methods). The average number of PTIs at the end of the 5 year period are shown in the rightmost figure for the HAR and LAR for the coupled (solid) and decoupled (dashed) frameworks. The top panel (A-F) corresponds to the HAR retaining all vaccines ($f = 0$), while the bottom panel (G-L) corresponds to equal vaccine sharing ($f = 0.5$). In all simulations, we take $\bar{R}_{0,\text{LAR}}/\bar{R}_{0,\text{HAR}} = 1.2$, $\eta = 0.01$, and assume that infection after waned natural immunity contributes primarily to evolution (i.e. $w_{IS} = 0.8$, $w_{IS1} = 0.2/x_e$, and $w_{IS2} = 0.2$). All other parameters are identical to those in Figure 4.

297 We note that assumptions of large \bar{R}_0 in the LAR also result in very large initial infection
298 peaks, which increase community immunity in the medium-term. These initial waves are not
299 reflected in the total case counts, however, since these values are summations from the time of
300 vaccine initiation through the end of the 5 year period after the onset of the pandemic. Further,
301 in Figure 5 we illustrate the temporal effect of the coupled framework on the infection dynamics
302 in the LAR and HAR relative to the first model with no immigration or explicit effect of PTIs
303 on the transmission rate. When moderate asymmetry in \bar{R}_0 is assumed ($\bar{R}_{0,LAR}/\bar{R}_{0,HAR} =$
304 1.2), simulations using the decoupled framework suggest that a strategy where the HAR retains
305 all vaccines would be highly beneficial for that country (top panel of Figure 5; no PTIs are
306 projected to occur, and low case numbers are observed throughout). However, this occurs at the
307 expense of PTIs and infection burden in the LAR, which are both substantially higher. With
308 the more realistic coupled framework, immigration and increases in transmission illustrate that
309 this strategy is far less beneficial to the HAR than the decoupled framework would suggest, as
310 substantially higher case numbers and PTIs are predicted in this region. Although total cases in
311 the HAR increase slightly when vaccines are equally distributed under the coupled framework
312 (lower panel of Figure 5), substantial reductions in case numbers in the LAR result in fewer
313 PTIs in that country, and total combined case numbers are also slightly lower. To untangle the
314 effects of immigration and PTIs on dynamics in the coupled framework, we reproduce Figures
315 4 and 5 allowing for immigration only in Figures S7 and S8, respectively. In other words, these
316 figures represent a more optimistic evolutionary scenario in which the occurrence of a PTI
317 does not increase transmission rates in either the HAR or LAR. Overall, we show that vaccines
318 play an important role in minimizing cases (particularly severe cases) as well as potential viral
319 adaptation in both regions. We also emphasize that imperfect vaccinal and natural immunity
320 and asymmetries in population size and transmission rates add many nuances to this picture.

321 **Caveats**

322 A full list of caveats and future directions is presented in Supplementary Materials; we briefly
323 summarize them below. First, building on prior work and in order to focus on qualitative
324 features, we ignore heterogeneities within countries, such as due to age (30) or superspread-
325 ing (31). Similarly, we have assumed simple scenarios for nonpharmaceutical interventions
326 as in (6). More granular, well-parameterized epidemiological models with these complexities
327 would lead to more accurate quantitative predictions. Furthermore, additional booster doses
328 may be administered that could alter population-level immune landscapes, and including these
329 in future models will be important for qualitative and quantitative predictions. Additionally,
330 we omit vaccine hesitancy (32), though simple extensions of our previous models with hesi-
331 tancy (5, 6) could examine the resulting interplay with vaccine nationalism. Furthermore, we
332 have assumed the simplest evolutionary models, both for determining potential viral adaptation
333 rates as well as for simulating potential increases in transmission rates. As more data become
334 available, these should be refined (33–36), with possible directions including extending the
335 model to explicitly track the transmission of different strains, and accounting for potential re-
336 ductions in the strength of vaccinal immunity (i.e. the parameters ϵ_{V_1} , ϵ_{V_2} , ϵ_1 , and ϵ_2) due to the
337 emergence of novel variants (37). Lastly, we assume that the seasonal transmission rates are
338 similar in both countries, though in reality they could differ. The online interactive application
339 (<https://grenfelllab.shinyapps.io/vaccine-nationalism/>) allows for an
340 in-depth exploration of the effect of different climate-driven seasonal transmission rates as well
341 as a broad range of assumptions related to NPIs and immuno-epidemiological parameters.

342

343 **Conclusion**

344 Even as vaccine production increases, a number of countries are choosing to share little or no
345 vaccines with countries that have very low vaccine availability. Vaccine nationalism, dosing
346 regimes, and host immune responses have important interactive effects, and these will substan-
347 tially shape epidemiological dynamics and evolutionary potential in the medium term. Addi-
348 tionally, unstable vaccine supply will also increase variability in the timing or availability of
349 first and second doses.

350

351 Using extensions of our prior work (5, 6), we incorporated vaccine sharing scenarios in two
352 countries whose infection dynamics are either otherwise independent or coupled through immi-
353 gration of infectious individuals and evolution-driven increases in transmission rates. When
354 country profiles are symmetric, we find that sharing vaccines with countries that have low
355 availability decreases overall infections and may also mitigate potential antigenic evolution.
356 Asymmetries in population size or transmission rates introduce additional complexities, which
357 are particularly marked when natural and vaccinal immunity is weak. Nevertheless, our mod-
358 els indicate that the redistribution of vaccine surpluses is likely advantageous in terms of epi-
359 demiological and evolutionary outcomes in both countries and, by extension, globally. Ethical
360 arguments also support this policy (11, 12). Persistent elevated disease transmission in coun-
361 tries with low vaccine availability also substantially undermines attempts at infection control
362 via stockpiling in the country with high vaccine availability, which is not accounted for when
363 disease transmission in both countries is assumed to be decoupled. Overall, our work high-
364 lights the importance of continued efforts in quantifying the robustness of immunity following
365 vaccination. Furthermore, reevaluation of stockpiling policies as vaccine supplies increase is
366 imperative, and ramping up global vaccination efforts is crucial.

367

368 **Supplementary Materials**

369 See attached documents.

370 **Acknowledgements**

371 This work was funded in part by Open Philanthropy, the Natural Sciences and Engineering
372 Research Council of Canada through a Postgraduate-Doctoral Scholarship (CMSR), the Co-
373 operative Institute for Modelling the Earth System (CIMES) (REB), the James S. McDonnell
374 Foundation 21st Century Science Initiative Collaborative Award in Understanding Dynamic and
375 Multi-scale Systems (CMSR, SAL), the C3.ai Digital Transformation Institute and Microsoft
376 Corporation (SAL), Gift from Google, LLC (SAL), the National Science Foundation (CNS-
377 2027908, CCF1917819) (SAL), the U.S. CDC (BTG), Flu Lab (BTG). **Author contributions:**
378 CEW, CMSR, BTG designed the study. CEW and CMSR performed the simulations and anal-
379 yses, and wrote the manuscript. SEM developed the Shiny application. All authors contributed
380 to interpreting the results and editing the manuscript. **Competing interests:** The authors have
381 no competing interests.

382 **References**

- 383 1. E. Dong, H. Du, L. Gardner, *The Lancet Infectious Diseases* **20**, 533 (2020).
- 384 2. F. P. Polack, *et al.*, *New England Journal of Medicine* **383**, 2603 (2020). PMID: 33301246.
- 385 3. M. Voysey, *et al.*, *The Lancet* **397**, 99 (2021).
- 386 4. L. R. Baden, *et al.*, *New England Journal of Medicine* (2020).
- 387 5. C. M. Saad-Roy, *et al.*, *Science* **370**, 811 (2020).
- 388 6. C. M. Saad-Roy, *et al.*, *Science* (2021).

- 389 7. C. M. Saad-Roy, S. A. Levin, C. J. E. Metcalf, B. T. Grenfell, *Journal of The Royal Society*
390 *Interface* **18**, 20200683 (2021).
- 391 8. D. P. Fidler, *Science* **369**, 749 (2020).
- 392 9. L. Eaton, *BMJ* **372** (2021).
- 393 10. J. Holder, Tracking coronavirus vaccinations around the world,
394 [https://www.nytimes.com/interactive/2021/world/](https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html)
395 [covid-vaccinations-tracker.html](https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html).
- 396 11. E. J. Emanuel, *et al.*, *Science* **369**, 1309 (2020).
- 397 12. E. J. Emanuel, F. Luna, G. O. Schaefer, K.-C. Tan, J. Wolff, *American Journal of Public*
398 *Health* **111**, 371 (2021). PMID: 33566663.
- 399 13. L. M. Herzog, O. F. Norheim, E. J. Emanuel, M. S. McCoy, *BMJ* **372** (2021).
- 400 14. M. J. Keeling, A. Shattock, *Epidemics* **4**, 78 (2012).
- 401 15. H. Mamani, S. E. Chick, D. Simchi-Levi, *Management Science* **59**, 1650 (2013).
- 402 16. M. Salathé, J. H. Jones, *PLoS Computational Biology* **6**, e1000736 (2010).
- 403 17. P. Klepac, R. Laxminarayan, B. T. Grenfell, *Proceedings of the National Academy of Sci-*
404 *ences* **108**, 14366 (2011).
- 405 18. P. Klepac, I. Megiddo, B. T. Grenfell, R. Laxminarayan, *Journal of The Royal Society*
406 *Interface* **13**, 20150907 (2016).
- 407 19. K. M. Bubar, *et al.*, *Science* **371**, 916 (2021).
- 408 20. N. Mulberry, P. Tupper, E. Kirwin, C. McCabe, C. Colijn, *medRxiv* p. 2021.02.23.21252309
409 (2021).

- 410 21. J. Zahradník, *et al.*, *bioRxiv* (2021).
- 411 22. A. Rambaut, *et al.*, *Virological.org* (2020). [https://virological.org/t/preliminary-genomic-](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)
412 [characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563)
413 [spike-mutations/563](https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563).
- 414 23. H. M. Korevaar, *et al.*, *medRxiv* (2020).
- 415 24. B. L. Rice, *et al.*, *Nature Medicine* **27**, 447 (2021).
- 416 25. J. M. Dan, *et al.*, *Science* (2021).
- 417 26. S. P. Anand, *et al.*, *Cell Reports Medicine* (2021).
- 418 27. V. Shinde, *et al.*, *New England Journal of Medicine* **0**, null (0).
- 419 28. C. A. Prete, *et al.*, *medRxiv* (2021).
- 420 29. C. J. Reynolds, *et al.*, *Science* p. eabh1282 (2021).
- 421 30. J. S. Lavine, O. N. Bjornstad, R. Antia, *Science* (2021).
- 422 31. R. Laxminarayan, *et al.*, *Science* **370**, 691 (2020).
- 423 32. C. E. Wagner, *et al.*, *Frontiers in Public Health* **8**, 975 (2020).
- 424 33. C. M. Saad-Roy, A. B. McDermott, B. T. Grenfell, *The Journal of Infectious Diseases* **219**,
425 S46 (2019).
- 426 34. K. Koelle, S. Cobey, B. Grenfell, M. Pascual, *Science* **314**, 1898 (2006).
- 427 35. E. M. Volz, S. L. Kosakovsky Pond, M. J. Ward, A. J. Leigh Brown, S. D. W. Frost, *Genetics*
428 **183**, 1421 (2009).
- 429 36. E. M. Volz, K. Koelle, T. Bedford, *PLOS Computational Biology* **9**, 1 (2013).

430 37. T. Kustin, *et al.*, *medRxiv* (2021).